As a result, combining CAF and TAN therapies can greatly decrease carcinogenesis [157].Additionally, both TGF-β and Axl stimulate CXCL5 production and neutrophil infiltration into HCC tissues, indicating that targeting this axis might be an effective approach against HCC development [158]. The gene discussed is AXL; the disease is hepatocellular carcinoma.